Thromboangiitis obliterans: An old disease in need of a new look

International Journal of Cardiology

Volumn 75, Issue SUPPL. 1, 2000, Pages

  Adar, R ^a,b   Papa, M Z ^a,b   Schneiderman, J ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiphospholipid antibodies; Buerger's disease; Diagnostic criteria; Hyperhomocysteinemia; Thrombophilia

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANGIOGRAPHY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD EXAMINATION; BUERGER DISEASE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; IMMUNOGENETICS; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; SMOKING; THROMBOPHILIA;

EID: 0034739031     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00185-6     Document Type: Article

References (16)

1. Papa MZ, Adar R. A critical look at thromboangiitis obliterans (Buerger's disease). Perspectives in Vasc Surg 1992;5:1-18.
2. Buerger L. Thrombo-angiitis obliterans: a study of the vascular lesions leading to pre-senile spontaneous gangrene. Am J Med Sci 1908;136:567-80.
3. Wessler S, Ming SC, Gurevich V, Freiman DG. A critical evaluation of thromboangiitis obliterans. The case against Buerger's disease. New Engl J Med 1960;262:1149-60.
4. McKusick VA, Harris WS, Ottesen OE et al. Buerger's disease, a distinct clinical and pathologic entity. J Am Med Assoc 1962;181:5-12.
5. Mozes M, Cahansky G, Doitsch V, Adar R. The association of atherosclerosis and Buerger's disease: a clinical and radiological study. J Cardiovasc Surg 1970;11:52-9.
6. Adar R, Papa MZ, Halpern Z et al. Cellular sensitivity to collagen in thromboangiitis obliterans. New Engl J Med 1983;308:1113-6.
7. Papa MZ, Bass A, Adar R et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): The role of tobacco antigen and the major histocompatibility complex. Surgery 1992;111:527-31.
8. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990;S IV:3-8.
9. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 1996;11:335-9.
10. Athanassiou P, McHale J, Dikeou S, Laffan M, Dantis P, Davies KA. Buerger's disease and protein S deficiency: Successful treatment with prostacyclin. Clin Exp Rheumatol 1995;13:371-5.
11. Doko S, Katsumura T, Fujiwara T, Inada H, Masaki H. Antiphospholipid antibody syndrome and vasoocclusive diseases. Int J Angiol 1995;4:55-60.
12. Stammler F, Diehm C, Hsu E, Stockinger K, Amendt K. The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically. Dtsch Med Wochenstr 1996;121:1417-23.
13. Siguret V, Alhenc-Gelas M, Aiach M, Fiessinger JN, Ganssen P. Response to DDAVP stimulation in thirteen patients with Buerger's disease. Thromb Res 1997;86:85-7.
14. Choudhury NA, Pietraszek MR, Hachiya T et al. Plasminogen activators and plasminogen activator inhibitor 1, before and after venous occlusion of the upper limb in thromboangiitis-obliterans. Thromb Res 1992;66:321-9.
15. Cailleux N, Guegan-Massardier E, Borg JY et al. Pseudothromboangiitis obliterans and qualitative protein S deficiency: Report of a case. J Mal Vasc 1996;21:47-9.
16. The European TAO Study Group. Oral Iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double blind, randomised, placebo controlled trial. Eur J Vasc Endovasc Surg 1998;15:300-7.